Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series
Transplantation Proceedings · 2026
DOI: 10.1016/j.transproceed.2026.01.020 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Carlos Palacios-Castelló und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure and Heart Transplant Unit, Cardiology Department, Virgen del Rocío University Hospital, Seville, Spain. Electronic address: car.pc@hotm…. Hauptthemen laut MEDLINE: Anticoagulants, Heart-Assist Devices, Heparin, Pipecolic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a rare but potentially fatal immune-mediated complication of heparin therapy. Its incidence is higher after left ventricular assist device (LVAD) implantation compared with other cardiac procedures. While bivalirudin is the most frequently reported alternative anticoagulant in this setting, evidence on argatroban use remains limited. We describe three cases of HIT following HeartMate 3 LVAD implantation, all managed with argatroban. RESULTS: Two patients were successfully transitioned to acenocoumarol (international normalized ratio 2-2.5) and discharged without hemocompatibility-related adverse events, without antiplatelet therapy. The third patient, with multiple thrombophilic disorders (homozygous G20210A prothrombin mutation, low protein C, positive lupus anticoagulant, and mild hyperhomocysteinemia), developed ventilator-associated pneumonia and septic shock, experienced mild bleeding at puncture and tracheostomy sites, and died postoperatively; anticoagulation transition was not achieved. In our cohort, HIT incidence was 10% overall (30 LVADs) and 15% among HeartMate 3 implants (20 LVADs), aligning with prior reports. CONCLUSIONS: Argatroban appears to be an effective and safe alternative anticoagulant for HIT after LVAD implantation, enabling platelet recovery without a significant increase in bleeding or thrombotic events. Differentiating complications attributable to HIT or argatroban from those inherent to LVAD support remains challenging, given the device's intrinsic risks of thrombosis, bleeding, and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Heart Failure and Heart Transplant Unit, Cardiology Department, Virgen del Rocío University Hospital, Seville, Spain. Electronic address: car.pc@hotmail.com.
- Heart Failure and Heart Transplant Unit, Cardiology Department, Virgen del Rocío University Hospital, Seville, Spain.
- Cardiac Surgery Department, Virgen del Rocío University Hospital, Seville, Spain.
- Intensive Care Unit Department, Virgen del Rocío University Hospital, Seville, Spain.
Zitieren
APA
Palacios-Castelló, C., Fernández-Gordon-Sánchez, S., Esteve-Ruiz, I., Grande-Trillo, A., Sobrino-Márquez, J. M., Adsuar-Gómez, A., Martín-Villén, L., & Rangel-Sousa, D. (2026). Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2026.01.020
Vancouver
Palacios-Castelló C, Fernández-Gordon-Sánchez S, Esteve-Ruiz I, Grande-Trillo A, Sobrino-Márquez JM, Adsuar-Gómez A, et al. Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2026.01.020
BibTeX
@article{PalaciosCastell2026,
author = {Palacios-Castelló, Carlos and Fernández-Gordon-Sánchez, Santiago and Esteve-Ruiz, Iris and Grande-Trillo, Antonio and Sobrino-Márquez, José Manuel and Adsuar-Gómez, Alejandro and Martín-Villén, Luis and Rangel-Sousa, Diego},
title = {Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series},
journal = {Transplantation Proceedings},
year = {2026},
doi = {10.1016/j.transproceed.2026.01.020}
}
EUVIMED